
Invitae Corporation NVTA
Quartalsbericht 2023-Q3
hinzugefügt 23.05.2026
Invitae Corporation Betriebsaufwand 2011-2026 | NVTA
Betriebsaufwand Jährlich Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 343 M | 190 M | 139 M | 97.4 M | 81.3 M | 43.3 M | 24.2 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 343 M | 24.2 M | 131 M |
Betriebsaufwand anderer Aktien in der Diagnostik & Forschung
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
Celcuity
CELC
|
172 M | $ 88.57 | -4.22 % | $ 4.14 B | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
50.6 M | $ 5.32 | -7.68 % | $ 7.08 M | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 21.2 | -1.85 % | $ 615 M | ||
|
Fulgent Genetics
FLGT
|
222 M | $ 19.02 | -2.46 % | $ 585 M | ||
|
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Guardant Health
GH
|
226 M | $ 126.28 | -5.1 % | $ 15.8 B | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
Interpace Biosciences
IDXG
|
20 M | $ 1.65 | -7.82 % | $ 7.3 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
411 M | $ 22.06 | -4.58 % | $ 1.18 B | ||
|
Illumina
ILMN
|
2.06 B | $ 161.86 | -3.69 % | $ 25.1 B | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 148.91 | -2.55 % | $ 11.7 B | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 101.99 | -0.81 % | $ 6.88 B | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
NeoGenomics
NEO
|
430 M | $ 10.82 | -4.33 % | $ 1.39 B | ||
|
Natera
NTRA
|
258 M | $ 215.8 | -2.84 % | $ 29.5 B | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 182.78 | -1.63 % | $ 9.06 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Pacific Biosciences of California
PACB
|
600 M | $ 1.4 | -13.85 % | $ 420 M | ||
|
Medpace Holdings
MEDP
|
118 M | $ 455.2 | -0.76 % | $ 13.1 B | ||
|
Mettler-Toledo International
MTD
|
1.01 B | $ 1 154.6 | -2.19 % | $ 23.8 B | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
964 M | $ 4.63 | -1.39 % | $ 429 M | ||
|
National Research Corporation
NRC
|
38.5 M | $ 19.56 | -0.96 % | $ 438 M | ||
|
Personalis
PSNL
|
44.5 M | $ 10.54 | -12.93 % | $ 941 M | ||
|
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 26.17 | 0.67 % | $ 24.8 B | ||
|
Senseonics Holdings
SENS
|
61.8 M | $ 6.63 | -5.49 % | $ 277 M | ||
|
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
181 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
5.64 M | $ 2.15 | 0.23 % | $ 4.94 M | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 266.2 | 1.95 % | $ 22.1 B | ||
|
Twist Bioscience Corporation
TWST
|
116 M | $ 68.92 | -6.78 % | $ 4.12 B | ||
|
Thermo Fisher Scientific
TMO
|
7.15 B | $ 474.12 | -1.65 % | $ 179 B | ||
|
Trinity Biotech plc
TRIB
|
28.3 M | $ 0.67 | -1.96 % | $ 241 M | ||
|
Motus GI Holdings
MOTS
|
19.1 M | - | -34.28 % | $ 263 K | ||
|
Waters Corporation
WAT
|
687 M | $ 367.04 | -2.49 % | $ 21.9 B | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 8.99 | -1.48 % | $ 1.95 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 201.12 | 2.53 % | $ 22.3 B |